SAN

88.23

+0.88%↑

MRK1

114.95

-0.39%↓

SHL.DE

46.57

+0.34%↑

ARGX

515.4

+0.98%↑

FRE

44.24

+0.07%↑

SAN

88.23

+0.88%↑

MRK1

114.95

-0.39%↓

SHL.DE

46.57

+0.34%↑

ARGX

515.4

+0.98%↑

FRE

44.24

+0.07%↑

SAN

88.23

+0.88%↑

MRK1

114.95

-0.39%↓

SHL.DE

46.57

+0.34%↑

ARGX

515.4

+0.98%↑

FRE

44.24

+0.07%↑

SAN

88.23

+0.88%↑

MRK1

114.95

-0.39%↓

SHL.DE

46.57

+0.34%↑

ARGX

515.4

+0.98%↑

FRE

44.24

+0.07%↑

SAN

88.23

+0.88%↑

MRK1

114.95

-0.39%↓

SHL.DE

46.57

+0.34%↑

ARGX

515.4

+0.98%↑

FRE

44.24

+0.07%↑

Search

Innate Pharma SA

Затворен

1.91 0.53

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

1.9

Максимум

1.91

Ключови измерители

By Trading Economics

Приходи

57K

-25M

Продажби

-8M

4.3M

EPS

-0.3

Марж на печалбата

-570.732

Служители

181

EBITDA

2.5M

-23M

Препоръки

By TipRanks

Препоръки

Неутрален

12-месечна прогноза

+61.67% upside

Пазарни показатели

By TradingEconomics

Пазарна капитализация

29M

183M

Предишно отваряне

1.38

Предишно затваряне

1.91

Техническа оценка

By Trading Central

Увереност

Weak Bullish Evidence

Innate Pharma SA Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

6.06.2025 г., 14:31 ч. UTC

Печалби

New York State Retirement Fund Posts 5.84% Annual Investment Return

6.06.2025 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

6.06.2025 г., 20:50 ч. UTC

Пазарно говорене

Auto & Transport Roundup: Market Talk

6.06.2025 г., 20:33 ч. UTC

Печалби

These Stocks Moved the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

6.06.2025 г., 19:36 ч. UTC

Пазарно говорене

Oil Futures Post Solid Weekly Gains -- Market Talk

6.06.2025 г., 19:28 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Rise on Demand Expectations -- Market Talk

6.06.2025 г., 18:46 ч. UTC

Пазарно говорене

Gold Faced With Tariff Uncertainty Offset by ETF Withdrawals -- Market Talk

6.06.2025 г., 18:02 ч. UTC

Пазарно говорене

U.S. Oil Rig Count Continues to Decline -- Market Talk

6.06.2025 г., 16:35 ч. UTC

Печалби

These Stocks Are Moving the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

6.06.2025 г., 16:34 ч. UTC

Печалби

These Stocks Are Moving the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

6.06.2025 г., 16:21 ч. UTC

Пазарно говорене

Canadian Unemployment Set to Continue Feel Trade War Pressures -- Market Talk

6.06.2025 г., 16:20 ч. UTC

Пазарно говорене

Auto & Transport Roundup: Market Talk

6.06.2025 г., 16:20 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

6.06.2025 г., 16:20 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

6.06.2025 г., 16:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

6.06.2025 г., 16:07 ч. UTC

Пазарно говорене

Market Talk Roundup: Latest on U.S. Politics

6.06.2025 г., 16:07 ч. UTC

Пазарно говорене

Base Metal Prices Slide But Copper Set to End Week Higher -- Market Talk

6.06.2025 г., 15:53 ч. UTC

Пазарно говорене

Mexican Inflation Seen Rising in May -- Market Talk

6.06.2025 г., 15:36 ч. UTC

Пазарно говорене

Dollar's Boost From U.S. Jobs Data Could Be Limited -- Market Talk

6.06.2025 г., 15:36 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

6.06.2025 г., 15:33 ч. UTC

Пазарно говорене

Gold Futures Slide After Jobs Data Surprises to Upside -- Market Talk

6.06.2025 г., 15:16 ч. UTC

Пазарно говорене

Tesla Showing Signs of Weakness in Key Regions -- Market Talk

6.06.2025 г., 15:05 ч. UTC

Пазарно говорене

Silver at its Highest In Nearly 15 Years -- Market Talk

6.06.2025 г., 14:35 ч. UTC

Пазарно говорене

Weakening Canadian Job Market Seen Keeping BoC in Easing Mode -- Market Talk

6.06.2025 г., 14:28 ч. UTC

Пазарно говорене

Bitcoin Rises After Above-Forecast U.S. Jobs Data -- Market Talk

6.06.2025 г., 14:28 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

6.06.2025 г., 14:28 ч. UTC

Пазарно говорене

Canada's Job Market Weakens But Not Seen Collapsing -- Market Talk

6.06.2025 г., 14:15 ч. UTC

Пазарно говорене

Oil Rises on U.S.-China Talks Optimism -- Market Talk

6.06.2025 г., 14:12 ч. UTC

Печалби

Palantir and Super Micro Computer Stocks Rise as Broadcom Posts Strong AI Revenue -- Barrons.com

6.06.2025 г., 14:09 ч. UTC

Печалби

Broadcom, the $1 Trillion Stock You Shouldn't Ignore, Makes AI Investment Case -- Barrons.com

Сравнение с други в отрасъла

Ценова промяна

Innate Pharma SA Прогноза

Ценова цел

By TipRanks

61.67% нагоре

12-месечна прогноза

Среден 3.104 EUR  61.67%

Висок 3.1 EUR

Нисък 3.1 EUR

Според 1 анализатори от Wall Street, предложили 12-месечна ценова цел за Innate Pharma SA през последните три месеца.

Консенсусна оценка

By TipRanks

Неутрален

1 ratings

0

Купи

1

Задържане

0

Продай

Техническа оценка

By Trading Central

1.91 / 2.1Подкрепа & съпротива

Краткосрочен план

Weak Bullish Evidence

Средносрочен план

Weak Bullish Evidence

Дългосрочен план

Bullish Evidence

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Innate Pharma SA

Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.